| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | 0.56 | 7e-58 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.3 | 1e-17 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.24 | 8e-12 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.28 | 4e-10 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-09 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.33 | 2e-08 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-06 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |